相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines tor diagnosis, treatment and follow-up
M. Dreyling et al.
ANNALS OF ONCOLOGY (2021)
Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma
Paolo Strati et al.
HAEMATOLOGICA (2020)
Follicular lymphoma: 2020 update on diagnosis and management
Arnold Freedman et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life
Clara Sortais et al.
ANNALS OF HEMATOLOGY (2020)
R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET
Patrizia Mondello et al.
BLOOD (2020)
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study
Ian W. Flinn et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
Emmanuel Bachy et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma
Brian T. Hill et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy
Emmanuel Bachy et al.
BLOOD (2018)
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety
Wolfgang Hiddemann et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma
Stefano Luminari et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Four versus Two Years of Rituximab Maintenance (R-Maintenance) Following Bendamustine Plus Rituximab (B-R): Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN Study)
Mathias Rummel et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
F. Morschhauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
R. Marcus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
Matthew J. Maurer et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
Vindi Jurinovic et al.
BLOOD (2016)
Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402
Michael E. Williams et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes
Lauren R. Teras et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study
Carla Casulo et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
Alessandro Pastore et al.
LANCET ONCOLOGY (2015)
Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5)
Morgane Mounier et al.
LANCET HAEMATOLOGY (2015)
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
Ian W. Flinn et al.
BLOOD (2014)
Conceptual and Technical Challenges in Network Meta-analysis
Andrea Cipriani et al.
ANNALS OF INTERNAL MEDICINE (2013)
R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi
Massimo Federico et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource
Brian K. Link et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel et al.
LANCET (2013)
On the Half-Cauchy Prior for a Global Scale Parameter
Nicholas G. Polson et al.
BAYESIAN ANALYSIS (2012)
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
Georgia Salanti et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
Gilles Salles et al.
LANCET (2011)
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
Massimo Federico et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Follicular lymphoma international prognostic index
P Solal-Céligny et al.
BLOOD (2004)
A random variance model for detection of differential gene expression in small microarray experiments
GW Wright et al.
BIOINFORMATICS (2003)
分享论文
